患有表皮生长因子受体突变 (EGFRm) 的晚期或转移性非小细胞肺癌 (NSCLC) 患者的群体特征,治疗模式和结果:IPO Porto的回顾性队列研究
Ana Rodrigues1, Marta Pina1, Rita Calisto2,3,4
1Medical Oncology Department, Portuguese Oncology Institute of Porto, 4200-072 Porto, Portugal.
Current oncology (Toronto, Ont.)
|August 27, 2025
概括
这项研究分析了晚期非小细胞肺癌 (NSCLC) 患者的表皮生长因子受体突变 (EGFRm). 实际生存期为18. 9个月,ECOG分数较高或EGFR突变较高的人的结果较差.
科学领域:
- 癌症学
- 医学研究
- 临床数据分析
背景情况:
- 晚期非小细胞肺癌 (NSCLC) 往往表现为转移性疾病,因此对于治疗选择来说,分子分析至关重要.
- 表皮生长因子受体突变 (EGFRm) 是NSCLC的关键点,影响治疗策略和患者的治疗结果.
研究的目的:
- 在晚期/转移性NSCLC患者中鉴定EGFR突变.
- 分析这些患者的治疗模式和实际结果.
- 确定影响EGFRm NSCLC存活时间的因素.
主要方法:
- 包括在综合护理中心在2018-2021年间诊断的成年人的回顾性队列研究.
- 使用卡普兰-梅尔方法分析事件发生时间的结果.
- 患者人口特征,疾病阶段,转移部位,表现状况和特定EGFR突变.
主要成果:
- 该队列 (n=110) 主要包括女性 (76.4%),非吸烟者 (83.2%),腺癌 (97.3%) 和第四阶段疾病 (93.6%).
- 在58. 2%的患者中存在EGFR外基因-19缺失; 81. 8%的患者接受了第一线息性全身治疗,主要是TKI (91. 1%).
- 实际总生存时间 (rwOS) 的中位数为18. 9个月. 更糟糕的rwOS与ECOG 2-4 (10. 3个月) 和exon-21 L858R突变 (15. 8个月) 有关.
结论:
- 这项研究强调了EGFRm高级NSCLC的现实特征和治疗模式.
- 患者表现状况 (ECOG) 和特定的EGFR突变类型显著影响现实生存率.
- 这些发现强调了分子分析和量身定制的治疗方法在高级NSCLC的管理中的重要性.
更多相关视频
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
8.9K
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
8.0K
相关概念视频
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K